There is no standard treatment for MEITL. Most individuals have been treated by surgical resections of involved areas with or without anthracycline-based chemotherapy. In these cases, responses have been short-lived and/or poor with 1 year overal survival rates, 1 year progression free survival rates, and median survival times of 36%, 21%, and 7 months, respectively. A retrospective study of patients treated with resection, chemotherapy and autologous hematopoietic stem cell transplantation had a higher 1-year and 5-year overall survival (100%, 33%) compared to one-year survival (73%) and five-year survival (14%) without transplantation; a second retrospective study supported the usefulness of transplantation in that high-dose lymphoma chemotherapy followed by transplantation and standard-dose lymphoma chemotherapy with or without surgical resection increased 5-year overall survival from 22 to 60% and 5-year disease progression-free survival from 22 to 52%. While further studies, particularly randomized controlled trials, are needed to investigate the best treatments for MEITL, the use of lymphoma chemotherapy, hematopoietic stem cell transplantation, and, where needed, surgical resections are the currently recommended treatments for MEITL.
Monomorphic epitheliotropic intestinal T cell lymphoma
Enteropathy-associated T-cell lymphoma
Duodenal-type follicular lymphoma
Hepatosplenic T-cell lymphoma
Splenic lymphoma with villous lymphocytes
Diffuse large B-cell lymphoma associated with chronic inflammation
Hereditary progressive mucinous histiocytosis
MALT lymphoma